Assessing the impact of HBV NAT on window period reduction and residual risk

[1] Estimated risk of transfusion-transmitted viral infections in Spain [J]. TRANSFUSION, 2002, 42 (08) : 994 - 998

[2] Comparative sensitivity of HBVNATs and HBsAg assays for detection of acute HBV infection [J]. TRANSFUSION, 2003, 43 (06) : 788 - 798

[3] A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors [J]. TRANSFUSION, 2005, 45 (02) : 254 - 264

[4] Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? [J]. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2004, 11 (01) : 26 - 32

[5] Caglioti S, 2004, TRANSFUSION, V44, p84A

[6] Coste J, 2005, VOX SANG, V88, P289, DOI 10.1111/j.1423-0410.2005.00636_1.x

[7] Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population [J]. TRANSFUSION, 2002, 42 (08) : 975 - 979

[8] International application of the incidence rate/window period model [J]. TRANSFUSION, 2002, 42 (08) : 966 - 972

[9] Kleimenova NG, 1996, GEOMAGN AERON+, V36, P52

[10] The incidence window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection [J]. TRANSFUSION MEDICINE REVIEWS, 1997, 11 (03) : 155 - 172

[1] Estimated risk of transfusion-transmitted viral infections in Spain [J]. TRANSFUSION, 2002, 42 (08) : 994 - 998

[2] Comparative sensitivity of HBVNATs and HBsAg assays for detection of acute HBV infection [J]. TRANSFUSION, 2003, 43 (06) : 788 - 798

[3] A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors [J]. TRANSFUSION, 2005, 45 (02) : 254 - 264

[4] Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? [J]. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2004, 11 (01) : 26 - 32

[5] Caglioti S, 2004, TRANSFUSION, V44, p84A

[6] Coste J, 2005, VOX SANG, V88, P289, DOI 10.1111/j.1423-0410.2005.00636_1.x

[7] Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population [J]. TRANSFUSION, 2002, 42 (08) : 975 - 979

[8] International application of the incidence rate/window period model [J]. TRANSFUSION, 2002, 42 (08) : 966 - 972

[9] Kleimenova NG, 1996, GEOMAGN AERON+, V36, P52

[10] The incidence window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection [J]. TRANSFUSION MEDICINE REVIEWS, 1997, 11 (03) : 155 - 172